Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HMPL-A83 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| HMPL-A83 injection | DRUG | Day 1,8,15,22 dose; 28 day treatment cycles. |
Top 20 of 45 competitors
HMPL-A83 is an investigational small molecule being studied for the treatment of advanced tumors. It is currently in Phase 1 clinical development for this oncology indication. The drug is not yet approved and remains under investigation.
HMPL-A83 is being developed by HUTCHMED (China) Limited, a biopharmaceutical company listed on the stock exchange under the ticker HCM. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced tumors.
HMPL-A83 is in Phase 1 clinical development. A Phase 1 study has been completed, involving 40 patients with advanced tumors. The drug is investigational and has not yet received regulatory approval.
HMPL-A83 has one completed clinical trial, registered under NCT05429008. This Phase 1 study, titled 'A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm,' enrolled 40 patients with advanced tumors. The trial was uncontrolled and not randomized or double-blinded.
No alternative names for HMPL-A83 have been reported. The drug is identified solely by its code name HMPL-A83 in clinical trial registries and development documentation.